159 related articles for article (PubMed ID: 29414302)
1. Imaging of human epidermal growth factor receptors for patient selection and response monitoring - From PET imaging and beyond.
Pereira PMR; Abma L; Henry KE; Lewis JS
Cancer Lett; 2018 Apr; 419():139-151. PubMed ID: 29414302
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
3. Roles of human epidermal growth factor receptor family in pulmonary lymphangioleiomyomatosis.
Kobayashi K; Miki Y; Saito R; Adachi K; Seyama K; Okada Y; Sasano H
Hum Pathol; 2018 Nov; 81():121-130. PubMed ID: 30030119
[TBL] [Abstract][Full Text] [Related]
4. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
[TBL] [Abstract][Full Text] [Related]
5. The HER family as therapeutic targets in colorectal cancer.
Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
7. PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.
Rinne SS; Orlova A; Tolmachev V
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33915894
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of ErbB/HER family proteins in patients with vulvar cancer.
Baiocchi G; de Freitas RR; Bovolim G; Badiglian-Filho L; da Costa AABA; De Brot L
Int J Gynaecol Obstet; 2022 Apr; 157(1):102-109. PubMed ID: 34270807
[TBL] [Abstract][Full Text] [Related]
9. Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.
Henry KE; Ulaner GA; Lewis JS
PET Clin; 2018 Jul; 13(3):423-435. PubMed ID: 30100080
[TBL] [Abstract][Full Text] [Related]
10. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
[TBL] [Abstract][Full Text] [Related]
11. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
[TBL] [Abstract][Full Text] [Related]
12. Expression and significance of HER family receptors in neuroblastic tumors.
Izycka-Swieszewska E; Wozniak A; Drozynska E; Kot J; Grajkowska W; Klepacka T; Perek D; Koltan S; Bien E; Limon J
Clin Exp Metastasis; 2011 Mar; 28(3):271-82. PubMed ID: 21203803
[TBL] [Abstract][Full Text] [Related]
13. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.
Claus J; Patel G; Ng T; Parker PJ
Biochem Soc Trans; 2014 Aug; 42(4):831-6. PubMed ID: 25109965
[TBL] [Abstract][Full Text] [Related]
14. Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors.
Carlsson J
Tumour Biol; 2012 Jun; 33(3):653-9. PubMed ID: 22228543
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
Sassen A; Rochon J; Wild P; Hartmann A; Hofstaedter F; Schwarz S; Brockhoff G
Breast Cancer Res; 2008; 10(1):R2. PubMed ID: 18182100
[TBL] [Abstract][Full Text] [Related]
16. HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study.
Makatsoris T; Tsamandas AC; Strimpakos A; Alexopoulou Z; Dionysopoulos D; Pervana S; Konstantara A; Papakostas P; Samantas E; Rallis G; Dimou A; Pentheroudakis G; Papaparaskeva K; Psyrri A; Kalogeras KT; Syrigos K; Scopa CD; Fountzilas G
Anticancer Res; 2016 Apr; 36(4):1581-90. PubMed ID: 27069134
[TBL] [Abstract][Full Text] [Related]
17. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma.
Hughes DP; Thomas DG; Giordano TJ; Baker LH; McDonagh KT
Cancer Res; 2004 Mar; 64(6):2047-53. PubMed ID: 15026342
[TBL] [Abstract][Full Text] [Related]
18. Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.
Francis DM; Huang S; Armstrong EA; Werner LR; Hullett C; Li C; Morris ZS; Swick AD; Kragh M; Lantto J; Kimple RJ; Harari PM
Clin Cancer Res; 2016 Feb; 22(3):633-43. PubMed ID: 26420857
[TBL] [Abstract][Full Text] [Related]
19. Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression.
Niu G; Cai W; Chen X
Front Biosci; 2008 Jan; 13():790-805. PubMed ID: 17981588
[TBL] [Abstract][Full Text] [Related]
20. Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging.
Sun X; Li S; Shen B
Curr Protein Pept Sci; 2016; 17(6):534-42. PubMed ID: 26721405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
